GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Infant Bacterial Therapeutics IBT B.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

72.80

-1.09%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Infant Bacterial Therapeutics

Its shares trade on Nasdaq Stockholm under the ticker IBT B.ST. It has been listed since 29 March 2016. In the fiscal year to 31 December 2024, it reported revenue of SEK 4,000 and a net loss of SEK 136.9m. At that date it held total assets of SEK 239.6m and shareholders' equity of SEK 170.3m.

Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Mar 2016
Employees
8

Leadership

Pay as last reported

  • Mr. Peter RothschildChairman of the Board, since 2011SEK 747,000
  • Mr. Staffan StroembergChief Executive OfficerSEK 6.1m
  • Ms. Maria EkdahlChief Financial Officer
  • Mr. Anders KronstromChief Operating Officer, since 2018
  • Ms. Margareta HagmanIndependent DirectorSEK 188,000
  • Ms. Eva IdenIndependent DirectorSEK 163,000
  • Mr. Anthon JahreskogIndependent DirectorSEK 218,000
  • Dr. Kristina NygrenIndependent DirectorSEK 163,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
18
Environment
20
Social
11
Governance
23
Carbon reduction policy
No
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Clinical stage pharmaceutical company focused on rare diseases in premature infants.
  • Develops IBP-9414, a drug candidate containing Lactobacillus reuteri for NEC prevention.
  • Headquartered in Stockholm with an IPO in 2016.

Weaknesses

  • Limited to 8 employees, indicating small operational scale.
  • Focus on a single drug candidate, IBP-9414, for NEC prevention.
  • IPO occurred in 2016, suggesting limited recent capital raising.

Opportunities

  • Potential market for NEC prevention drugs in premature infant care.
  • Growing focus on rare disease treatments in pharmaceuticals.
  • Clinical development stage allows for potential partnerships or acquisitions.

Threats

  • Dependence on a single drug candidate, IBP-9414, for success.
  • Competition in the rare disease treatment sector.
  • Regulatory challenges in drug development for premature infants.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.